comparemela.com

Latest Breaking News On - Bernard briskin distinguished director - Page 1 : comparemela.com

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A 02 expression.

BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

City of Hope Doctors Present Novel Treatments for Bladder, Blood and Other Cancers at American Society of Clinical Oncology Annual Conference

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.